igxt - Pagina 34
Outlook Kairos: contesto sfidante anche i prossimi mesi, Fugnoli individua l’elemento che in futuro innescherÓ la svolta per Fed e mercati
Siamo quasi giunti al termine di un anno che rimarrÓ nella storia per diversi motivi, dalla guerra in Ucraina, all?inflazione sui massimi da decenni, ma anche per le performance negative dei mercati, con nessuna asset class che Ŕ riuscita a sfuggire alle vendite. Il mercato obbligazionario a livello globale ha registrato un -20% nominale da
Impennata rendimenti Btp rende meno attraenti gli yield di Enel e delle altre utility di Piazza Affari. Pesa anche il rebus bollette/pagamenti
Alea iacta est, il dado Ŕ tratto. Il timore di stop delle forniture di gas dalla Russia si era giÓ concretizzato con l?annuncio da parte di Gazprom della chiusura a tempo indeterminato di Nord Stream 1, come risposta di Putin al tetto al prezzo del petrolio russo deciso dai Paesi del G7. Nella giornata di
UniCredit, Orcel su governo Meloni: ‘mercati esagerati con Italia, cresce pi¨ di Italia e Germania e ricchezza famiglie supera 10.000 MLD’
Il numero uno di UniCredit Andrea Orcel conferma di riporre fiducia  nelle potenzialità dell'Italia e non vede grandi problemi per il paese dop
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #331
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,306
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949687

  2. #332

  3. #333
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,306
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949687
    IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March 23

  4. #334

    Data Registrazione
    Oct 2006
    Messaggi
    1,004
    Mentioned
    0 Post(s)
    Quoted
    0 Post(s)
    Potenza rep
    42949688
    Citazione Originariamente Scritto da playars Visualizza Messaggio
    IntelGenx to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Financial Results on Wednesday, March 23
    Ottimi risultati azienda in crescita, -20% crollo dell'azione da 0,60$ a 0,48$

    Non si riesce a decollare, qualcuno mi sa dire come mai???

  5. #335
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,246
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949690
    Citazione Originariamente Scritto da monicaF Visualizza Messaggio
    Ottimi risultati azienda in crescita, -20% crollo dell'azione da 0,60$ a 0,48$

    Non si riesce a decollare, qualcuno mi sa dire come mai???
    buongiorno,,,,,

    tutto bene?


    dimenticala per tutto il 2016
    vedrai che poi il portafoglio lo troverai gonfio sperem!!!!!!
    ottima azienda igxt
    Ŕ solo questione di tempo

    IntelGenx Corp., (TSX VENTURE:IGX)(IGXT), today announced the signing of a term sheet with a global pharmaceutical company for the development and commercialization of up to three products utilizing IntelGenx' proprietary VersaFilmÖ technology. Pursuant to the term sheet, IntelGenx granted an exclusive negotiation period during which time the parties will conduct diligence and work towards entry into a definitive agreement. IntelGenx receives $100,000 at the time of signing the term sheet, in consideration for granting an exclusive negotiation right. If entered into, IntelGenx expects the definitive agreement to be finalized by the second quarter of 2016.

    According to the term sheet, IntelGenx will grant exclusive rights to market and sell up to three products in the United States. The term sheet contemplates that IntelGenx will receive, in consideration for such exclusive rights, upfront and milestone payments, together with a share of profits, and also contemplates transfer of development costs to the counter-party. Entry into a definitive agreement remains subject to satisfaction of diligence by each party.

  6. #336
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,246
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949690

  7. #337
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,246
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949690
    IntelGenx to Report Second Quarter 2016 Financial Results on August 11, 2016

  8. #338

  9. #339
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,246
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949690
    amica prox gambetta
    dollarand$$$$$$


    $.86

  10. #340
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,246
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949690
    $.90 la paura

    IntelGenx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and the 11th Annual Singular Research ConferenceFont
    9:53 AM ET 9/7/16 | Marketwired
    SAINT-LAURENT, CANADA--(Marketwired - Sep 7, 2016) - IntelGenx Corp., (TSX VENTURE:IGX) (OTCQX:IGXT), today announced that Dr. Horst Zerbe, President and Chief Executive Officer, will present at two upcoming conferences. Also present and available for questions will be Andre Godin, Executive Vice-President and Chief Financial Officer.

    Rodman & Renshaw 18th Annual Global Investment Conference

    Date: Monday, September 12

    Location: Lotte New York Palace Hotel, New York City

    Presentation Time: 10:50 AM Eastern Time

    11th Annual Singular Research Conference "Best of the Uncovereds"

    Date: Thursday, September 22

    Location: Luxe Sunset Boulevard Hotel, Los Angeles

    About IntelGenx:

    IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmÖ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.

    IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilmÖ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.

    Forward Looking Statements:

    This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.

    Source: IntelGenx Technologies Corp.

    Edward Miller Director, IR and Corporate Communications IntelGenx Corp. +1 514-331-7440 (ext. 217) edward@intelgenx.com

Accedi